No Data
Biocause Pharmaceutical's Insurance Arm Accumulates 35 Billion Yuan in 2024 Insurance Premium Income
Hubei Biocause Pharmaceutical (000627.SZ): CHINA BEST Life Insurance's cumulative original insurance premium income in 2024 is approximately 34.639 billion yuan.
Hubei Biocause Pharmaceutical (000627.SZ) issued an announcement that its holding subsidiary CHINA BEST Life Insurance Co., Ltd. 20...
It's Down 27% But Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Could Be Riskier Than It Looks
hubei biocause pharmaceutical (000627.SZ) appointed Long Fei as General Manager and CFO.
Hubei Biocause Pharmaceutical (000627.SZ) announced that the board of directors will hold the tenth session on December 6, 2024...
A-shares midday review: The Shanghai index climbed back above 3400 points, the chinext price index rose by 2.49%, and the AIGC concept saw a full breakout.
As of noon, the Shanghai Composite Index rose 1.23% to 3410.36 points, the Shenzhen Component Index rose 1.79%, and the chinext price index rose 2.49%.
Hubei Biocause Pharmaceutical (000627.SZ): has not yet repurchased the company's shares.
Gelonghui December 2nd| Hubei Biocause Pharmaceuticals (000627.SZ) announced that as of the close of November 29, 2024, the company's stock price was 4.19 yuan per share, exceeding the upper limit of the company's stock repurchase price. The company has repurchased a total of 0 shares of the company's stock through a designated securities account for stock repurchase using centralized bidding trading, accounting for 0.00% of the company's current total share capital.
